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Abstract. This experiment was designed to characterize 
the withdrawal syndrome produced by discontinuation 
of treatment with escalating, non-neurotoxic doses of 
d-amphetamine (AMPH). AMPH withdrawal was asso- 
ciated with both transient and persistent changes in be- 
havior and postmortem brain tissue catecholamine con- 
centrations. During the first week of withdrawal rats 
showed a significant decrease in spontaneous nocturnal 
locomotor activity. This behavioral depression was most 
pronounced on the first 2 days after the discontinuation 
of AMPH pretreatment, was still evident after 1 week, 
but had dissipated by 4 weeks. Behavioral depression was 
not due to a simple motor deficit, because AMPH- 
pretreated animals showed a normal large increase in 
locomotion when the lights initially went out, but they 
did not sustain relatively high levels of locomotor activity 
throughout the night, or show the early morning rise in 
activity characteristic of controls. Behavioral depression 
was associated with a transient decrease in the concentra- 
tion of norepinephrine (NE) in the hypothalamus, and a 
transient decrease in the ability of an AMPH challenge 
to alter dopamine (DA) concentrations in the caudate- 
putamen and nucleus accumbens. AMPH pretreatment 
also produced persistent changes in brain and behavior. 
The persistent effects of  AMPH were not evident in 
spontaneous locomotor activity, but were revealed by a 
subsequent challenge injection of AMPH. AMPH pre- 
treated animals were markedly hyper-responsive to the 
stereotypy-producing effects of an AMPH challenge. 
This behavioral sensitization was not fully developed 
until 2 weeks after the discontinuation of AMPH pre- 
treatment, but then persisted undiminished for at least 
1 year. It is suggested that the transient changes in brain 
and behavior described here may represent an animal 
analogue of the "distress syndrome" seen in humans 
during AMPH withdrawal, which is associated with 
symptoms of depression and alterations in catecholamine 
function. On the other hand, persistent behavioral sen- 
sitization may be analogous to the enduring hypersen- 
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sitivity to the psychotogenic effects of AMPH seen in 
former AMPH addicts. 
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The abrupt discontinuation of chronic amphetamine 
(AMPH) use has both transient and persistent effects on 
behavior. In humans, the relatively transient "with- 
drawal" or "distress" syndrome is characterized by 
symptoms indicative of depression, including psycho- 
motor alterations, dysphoria, anxiety, anhedonia and 
anergia (Utena 1966; Kramer et al. 1967; for review see 
Gawin and Ellinwood 1988). These symptoms usually 
dissipate in a few weeks, but there are also very persistent 
sequelae associated with AMPH abuse, characterized by 
a hypersensitivity (sensitization) to its psychotogenic ef- 
fects (Utena 1966; Segal and Schuckit 1983). For exam- 
ple, re-exposure to a relatively low dose of AMPH, even 
after years of abstinence, will often reinstate psychotic 
symptoms in former AMPH addicts (Sato et al. 1983). 
Post-AMPH withdrawal depression and AMPH 
psychosis are thought to reflect neuronal adaptations to 
chronic drug treatment, but it is difficult to study these 
in humans. Thus, animal models of post-AMPH with- 
drawal depression and AMPH psychosis have been used 
to identify and study changes in neural activity and 
behavior precipitated by the discontinuation of AMPH 
treatment (Segal and Schuckit 1983 ; Robinson and Beck- 
er 1986; Kokkinidis 1988). One popular model involves 
intermittent injections (1 or 2 times per day or less) of a 
relatively low (1-5 mg/kg) constant dose of AMPH 
(Magos 1969; Segal and Mandell 1974; Klawans and 
Margolin 1975). This paradigm has proven particularly 
valuable in studying behavioral sensitization and its 
neurobiologicat correlates (Robinson and Becker 1986 
for review). Nevertheless, the constant low dose regimen 
has limitations as an animal model of human drug use. 
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Many AMPI-I addicts escalate their dose over time, ev- 
entually to quite high levels (Kramer et al. 1967; Ellin- 
wood 1972), and the constant low dose regimen does not 
reflect this pattern of use. It may be important to mimic 
this pattern of use because the neurochemical effects of 
high doses of AMPH are altered by pretreatment with 
gradually escalating doses (Schmidt et al. 1985). 
We recently reported that following the discontinua- 
tion of treatment with non-neurotoxic escalating doses of 
AMPH rats showed a depression in spontaneous noctur- 
nal locomotor activity for up to 5-10 days, and a hyper- 
sensitivity to a challenge injection of AMPH for up to 
21 days (Robinson and Camp 1987; Robinson et al. 
1988). This treatment regimen may provide, therefore, a 
good model for studying both the transient changes in 
brain and behavior seen early after withdrawal from 
AMPH, perhaps reflecting the depressive symptomatol- 
ogy reported in humans, as well as the persistent changes 
in brain and behavior exemplified by sensitization and 
the susceptibility to AMPH psychosis. The temporal 
profile of changes in brain and behavior associated with 
withdrawal from non-neurotoxic escalating dose AMPH 
treatment has not been well characterized, however, and 
this was the purpose of the studies reported here. 
Materials and methods 
Subjects. Adult female Holtzman rats (Holtzman Co., Madison, 
WI) weighing 200-260 g at the start of the experiment were housed 
individually in wire-hanging cages in a temperature-controlled 
room maintained on a normal light: dark cycle (14:10 hours; lights 
on at 05: 00 hours). The animals had free access to food and water. 
Amphetamine pretreatment regimen. AMPH-pretreated rats re- 
ceived twice daily intraperitoneal injections of d-amphetamine sul- 
fate (AMPH) in their home cage, with approximately 8 h separating 
the two injections. To mimic the pattern of drug use seen in addicts 
(repeated "runs" followed by a "crash"; Kramer et al. 1967) injec- 
tions were given each weekday, but not on weekends, and the dose 
of AMPH escalated from I to 10 mg/kg (weight of the salt) 
over 42 days (30 injection days) according to the schedule illus- 
trated graphically in Fig. 1. Control animals received 1 ml/kg 0.9 % 
saline/injection. 
Quantification of  behavior. Spontaneous and drug-induced loco- 
motor activity, and drug-induced stereotyped behavior, were quan- 
tified. Locomotor activity was quantified using automated activity 
monitors (41 x 24x 18 cm) equipped with two pairs of infrared 
photocells mounted along the long axis of the cage, 5.0 cm above 
the cage floor and 25.2 cm apart from each other. Disruption of a 
beam registered a single count, but another count could not be 
registered by that beam until the second photocell beam at the other 
end of the cage was disrupted. Therefore, activity counts in this ap- 
paratus reflect locomotion ("crossovers") from one end of the cage 
to the other, and not the repetitive disruption of one beam. 
Drug-induced stereotyped sniffing and stereotyped head and 
limb movements were rated independently by observers blind as to 
pretreatment condition, using the following five point rating scale: 
0) normal in place activity, 1) mild, discontinuous stereotyped 
behavior (sniffing or repetitive head and limb movements), 2) 
moderate, discontinuous stereotyped behavior, 3) moderate, con- 
tinuous stereotyped behavior and 4) intense, continuous stereo- 
typed behavior directed at one place. The two observers assigned 
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Fig. 1. Graphic representation of the escalating dose amphetamine 
(AMPH) pretreatment regimen (see Methods). Each open circle 
represents: (1) a day on which AMPH pretreated animals received 
two injections of d-AMPH sulfate with each injection separated by 
at least 8 h, and (2) the dose of each injection. On days when the 
dose equals zero (closed circles) animals did not receive injections. 
Control animals received saline injections according to the same 
schedule. This regimen mimics to some extent the pattern of "runs" 
and "crashes" seen in addicts (Kramer et al. 1967) 
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Experiment 1 ." Withdrawal from AMPH:  effects on the behav- 
ioral response to a subsequent A M P I I  challenge. At 2, 6, 13, 27, 89 
or 179 days following the cessation of AMPH pretreatment in- 
dependent groups of animals (N = 5-7/group) were placed individu- 
ally in the activity monitors described above, and allowed to habit- 
uate overnight. The next morning at 08:30 hours baseline loco- 
motor activity was recorded for 1 h, after which all animals received 
a challenge injection of 2.6 mg/kg AMPH. AMPH-induced locomo- 
tion was measured over 5-rain intervals for the next 3 h, and 
stereotyped behavior was rated at 10 min following drug injection 
and every 20 min thereafter, until ten rating scores had been ob- 
tained. A challenge dose of 2.6 mg/kg was used because pilot studies 
established this was the highest dose that produced primarily 
heightened locomotion (and not focused stereotyped behavior) in 
naive animals. With this challenge dose, therefore, behavioral sen- 
sitization is apparent as a qualitative change in behavior, i.e., the 
emergence of focused stereotyped behavior in AMPH pretreated 
animals (Segal t 975). A separate group of animals were also tested 
1 year after the discontinuation of pretreatment (see Results). We 
did not "challenge" a group of animals with saline because in 
previous experiments and pilot studies using this apparatus we 
found that this had negligible effect (e.g., see Fig, 3 in Camp and 
Robinson 1988), and that baseline scores provided just as meaning- 
ful a comparison. 
Experiment 2: Withdrawal from AMPH:  effects on spontaneous 
day~night locomotor activity, the response to an A M P H  challenge and 
the postmortem tissue concentrations of  monoamines and monoamine 
metabolites. In a second experiment animals were pretreated with 
AMPH or saline, as described above, or left unhandled. One sub- 
group of animals was placed into the activity monitors immediately 
after receiving their last pretreatment injection and spontaneous 
locomotor activity was monitored continuously for 21.5 h per day 
over 30-rain intervals, for either the next 3 or 7 days (separate 
subgroups). A third group was placed into the monitors 22 days 
after the cessation of drug treatment and spontaneous locomotor 
activity monitored between days 23 and 28 (inclusive). After this, 
half the animals in each of the three subgroups received a challenge 
injection (IP) of 2.6 mg/kg AMPH, and half received an injection 
of saline (between 08: 45 and 10:00 hours; N =  at least 8/group). 
Stereotyped behavior was rated only once, 40 min after the injec- 
tion. All animals were then killed immediately by decapitation and 
brain tissue obtained for neurochemical analysis. Animals were 
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killed 40 rain after the drug challenge because it was determined in 
experiment 1 that AMPH had its peak behavioral effect at this time. 
Postmortem tissue assay. Following decapitation the brain was 
rapidly removed and placed into ice cold saline for 30-45 s. It was 
then placed into a chilled cutting block and coronal sections were 
obtained as described by Heffner et al. (t980). The following regions 
were dissected in ice-cold saline: (a) medial frontal cortex, consist- 
ing of the DA-rich anteromedial portion of the frontal cortex from 
the genu of the corpus callosum to the frontal pole; (b) nucleus 
accumbens, removed with a 2 mm diameter micropunch; (c) cau- 
date-putamen, the corpus of the striatum was removed with a 3 mm 
micropunch; and (d) hypothalamus: the entire hypothalamus was 
removed by making a horizontal cut at the level of the rhinal fissure 
and vertical cuts lateral to the optic tracts (Heffner et aL 1980). 
Tissue from the left and right hemispheres was pooled, weighed and 
placed into tubes containing 0.05 N HC10~, with dihydroxy- 
benzylamine added as an internal standard. The tissue was assayed 
for norepinephrine (NE), dopamine (DA), dihydroxyphenylacetic 
acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine 
(5 HT) and 5-hydroxyindoleacetic acid (5-HIAA), using HPLC 
and electrochemical detection, although all compounds were not 
detectable in all structures. 
Data analysis. Locomotor and neurochemical data were analyzed 
using parametric statistics, including analyses of variance and Fi- 
sher's Least Significant Difference (LSD) test for follow-up pairwise 
comparisons (Wirier 1971). Because stereotyped behavior rankings 
only comprise an ordinal scale, these were analyzed using non- 
parametric statistics, including the Kruskal-Wallis and Mann-Whit- 
ney U tests. To control for multiple Mann-Whitney U tests a 
conservative significance level of e =0.01 was used, and all com- 
parisons were based on two-tailed probabilities. 
Results 
Withdrawal f rom A M P H :  Effects on the behavioral 
response to a subsequent A M P H  challenge 
The ability of  an A M P H  challenge to produce stereo- 
typed behavior at different points in time after the dis- 
continuation of  chronic A M P H  treatment  is illustrated 
in Fig. 2. The same results were obtained for stereotyped 
sniffing as for stereotyped head and limb movements ,  
and therefore only the ratings for stereotyped head and 
limb movements  are shown. The A M P H  challenge did 
not produce continuous (focused) stereotyped behavior  
at any time following the termination of  pre t rea tment  in 
saline pretreated rats (i.e., the peak stereotypy rating was 
always <2).  Three days after the discontinuation of  
pretreatment  an A M P H  challenge also failed to induce 
focused stereotyped behavior  in AMPH-pre t rea ted  rats, 
and there was no significant difference between the two 
groups at this point  in time (Fig. 2). By 7 days of  with- 
drawal there was a small, but statistically significant, 
difference in the stereotypy ratings of  saline- and A M P H -  
pretreated animals, a l though AMPH-pre t rea ted  rats still 
did not  show focused stereotypy. In contrast,  a marked  
effect of  A M P H  pretreatment  was apparent  by 14 days, 
and this persisted undiminished for at least 6 months.  
During this latter period (14-180 days after discontinua- 
tion of  p r e t r e a t m e n t ) t h e  A M P H  challenge produced 
intense, focused stereotyped behavior  in A M P H -  
pretreated animals, but not in controls (Fig. 2). 
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Fig. 2A-F. Mean (±SEM) ratings for stereotyped head and limb 
movements for saline (open symbols)- and AMPH (closed sym- 
bols)- pretreated rats before (interval 0) and after a challenge injec- 
tion of 2.6 mg/kg AMPH given 3, 7, 14, 28, 90 or 180 days after the 
discontinuation of pretreatment (N = 5-7/group). Mann-Whitney U 
tests were used to compare the cumulative rating for each AMPH- 
pretreated group to its respective control group. There was no 
difference in AMPH-induced stereotyped behavior between saline 
and AMPH-pretreated animals 3 days after discontinuation of 
AMPH pretreatment (U = 14, P=0.6). By 7 days of withdrawal 
AMPH-pretreated animals had significantly higher stereotypy 
ratings than did saline-pretreated animals (U = 13, P < 0.01). Signifi- 
cant group differences were also found 14, 28, 90 and 180 days after 
the discontinuation of AMPH pretreatment (U's = 0-3, P< 0.005). 
• Amphetamine - pretreatment; o control 
Similar group differences were apparent  in the auto- 
mated measure of  locomotor  activity. Fig. 3 shows that 
the A M P H  challenge increased locomotion in saline- 
pretreated rats at all times after the discontinuation of  
pretreatment.  Similarly, at 3 and 7 days after the discon- 
t inuation of pretreatment  the A M P H  challenge produced 
only locomotor  hyperactivity in AMPH-pre t rea ted  rats, 
and there were no significant group differences. But by 
14 days a marked  effect o f  A M P H  pretreatment  was 
apparent ,  and this persisted undiminished for at least 
180 days (Figs. 3 and 4). Between 14 and 180 days 
AMPH-pre t rea ted  rats showed complex multiphasic 
changes in locomotor  activity in response to an A M P H  
challenge, characterized in par t  by an initial increase in 
locomotion (5-15 rain) followed by a marked  decline in 
locomotion (20 60 min). During the period of  reduced 
locomotion AMPH-pre t rea ted  animals engaged in foc- 
used stereotyped behavior  (compare Figs. 2 and 3). Thus, 
the magni tude of  the decrease in locomotor  activity 
during the "stereotypy phase" provides an objective in- 
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Fig. 3A-F. The average number of crossovers (locomotion from one 
side of the cage to the other) cumulated over 5-min intervals during 
1 h of baseline and for 3 h after a challenge injection of 2.6 mg/kg 
AMPH, in saline (open symbols)- and AMPH (closed symbols)- 
pretreated animals tested 3, 7, 14, 28, 90 or 180 days after the 
discontinuation of pretreatment (N=6-7/group). There was no 
difference in baseline locomotor activity between saline- and 
AMPH-pretreated animals at any time following the cessation of 
AMPH pretreatment (2-way ANOVAs). Two-way ANOVAs (with 
repeated measures) were also used to compare AMPH-stimulated 
locomotor activity for each AMPH-pretreated group to its respec- 
tive control group. There was no effect of AMPH pretreatment on 
AMPH-induced locomotor activity 3 or 7 days after the discon- 
tinuation of AMPH pretreatment (F's < 0.5; NS = nonsignificant). 
Significant group differences were apparent by 14 days of 
withdrawal (F= 2.03, P < 0.001), because AMPH-pretreated rats 
showed a significant decline in locomotor activity during the period 
from about 20-60 min after drug injection, during which time they 
engaged in focused stereotyped behavior (all significant 
Fvalues represent a group by time interaction; see text and Fig. 2). 
Significant group differences were also found 28 (F= 3.4, P < 0.001), 
90 (F= 3.4, P<0.001) and 180 days (F= 3.67, P<0.001) after the 
discontinuation of AMPH pretreatment. • Amphetamine - pre- 
treated; O control 
focused s t e reo typed  b e h a v i o r  (Segal 1975). The  effects o f  
an  A M P H  chal lenge on  b o t h  s t e r eo typy  ra t ings  and  
" s t e r eo typy  phase"  l o c o m o t o r  ac t iv i ty  a re  summa r i z e d  
as a func t ion  o f  t ime af ter  the  d i s con t i nua t i on  o f  pre-  
t r e a tmen t  in Fig .  4. 
A th i rd  charac te r i s t i c  o f  A M P H - i n d u c e d  l o c o m o t o r  
ac t iv i ty  of ten  seen in A M P H - p r e t r e a t e d  an ima l s  is the  
p h e n o m e n o n  o f  p o s t - s t e r e o t y p y  hype rac t i v i t y  (Segal 
1975). This  refers to  a second  p e r i o d  o f  increased  loco-  
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Fig. 4. Summary of the effect of pretreatment with saline or AMPH 
on stereotypy phase locomotor activity (left) and stereotypy ratings 
(right) produced by a challenge injection of 2.6 mg/kg AMPH given 
3, 7, 14, 28, 90 or 180 days after discontinuation of pretreatment. 
Left: Bars in the left panel depict the average (+SEM) number of 
crossovers cumulated during the stereotypy phase (10-60 min post- 
injection) for AMPH-pretreated animals withdrawn for 3-180 days. 
The horizontal dashed line represents the average number of cross- 
overs for the pooled control group (n = 38) and the vertical line to 
the right + SEM for the controls. A one-way analysis of variance 
comparing all groups was significant (F=3.58, P<0.004). The 
asterisks (*) indicate that relative to the control group AMPH- 
pretreated animals showed a significant decrease in stereotypy 
phase locomotor activity 14, 28, 90 and 180 days, but not 3 or 7 
days, after the cessation of AMPH pretreatment (P < 0.05, Fisher's 
LSD tests). No other comparisons were statistically significant. 
Right: Bars in the right panel depict the average (+ SEM) rating for 
stereotyped head and limb movements cumulated over the entire 
test session following an AMPH challenge in AMPH-pretreated 
rats withdrawn for 3-180 days. For ease of comparison the average 
stereotypy rating for the pooled control group is indicated by the 
horizontal dashed line and :k SEM by the vertical line to the far 
right. The asterisks (*) indicate that AMPH-pretreated rats had 
significantly higher stereotypy ratings than controIs between 7 and 
180 days of withdrawal, but not after 3 days of withdrawal 
(* P<0.01; ** P<0.005,; see Fig. 2 for U values). The dagger (t) 
indicates that animals withdrawn for 3 or 7 days (which did not 
differ from one another, U= 24) had a significantly lower cumula- 
tive stereotypy rating than did those withdrawn for 14-180 days 
(Kruskal-Wallis test across the six AMPH-pretreated groups, 
H=27, df=5, P<0.001; follow-up Mann-Whitney U tests, 
U's = 1-9, P<0.01) 
m o t i o n  seen fo l lowing  the s t e reo typy  phase .  In teres t ing-  
ly, only  A M P H - p r e t r e a t e d  ra ts  w i t h d r a w n  for  28 days  
showed  signif icant  pos t - s t e r e o typy  hyperac t iv i ty  (see fig- 
ure  3D).  This  p a t t e r n  o f  b e h a v i o r  was n o t  seen in con t ro l  
an ima l s  a t  a n y  t ime,  o r  in A M P H - p r e t r e a t e d  an imals  
3-14 days  o r  3 -6  m o n t h s  af te r  the  d i s c on t i nu a t i on  o f  
p r e t r e a t m e n t  (also see Lei th  and  Kuczensk i  1982). 
F ina l ly ,  an  i n d e p e n d e n t  g r o u p  o f  an imals ,  as pa r t  o f  
a separa te  exper iment ,  received the same A M P H  pre-  
t r e a tmen t  reg imen desc r ibed  above ,  and  were  then  left 
u n d i s t u r b e d  for  1 year .  Af t e r  the last  p r e t r e a t m e n t  injec- 
t ion these an ima l s  were  housed  in pa i rs  to min imize  the  
stress o f  i so la t ion .  One  yea r  fo l lowing  the cessa t ion  o f  
A M P H  p r e t r e a t m e n t  the  an imals  received a chal lenge 
in jec t ion  o f  2.6 m g / k g  (IP) o f  A M P H ,  and  b e h a v i o r  was 
r eco rded  as descr ibed  above .  A M P H - p r e t r e a t e d  ra ts  
showed  a s ignif icant ly  grea ter  response  to the A M P H  
chal lenge than  d id  sa l ine -p re t rea ted  con t ro l s ,  as in- 
d i ca ted  by  b o t h  s t e r eo typy  ra t ings  a n d  a p e r i o d  o f  re- 
duced  l o c o m o t o r  ac t iv i ty  2 0 9 0  min  af te r  the  A M P H  
chal lenge (Fig.  5). F u r t h e r m o r e ,  the enhanced  response  
was as g rea t  as tha t  seen be tween  2 weeks and  6 m o n t h s  
484 
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Fig. 5A, B. The effect of pretreatment with saline (open symbols, 
n = 6) or A M P H  (closed symbols, n = 6) on crossovers (locomotor 
activity) and stereotyped behavior after a challenge injection of  
2.6 mg/kg AMPH (IP) given 1 year after the cessation of pretreat- 
ment. Left: The left panel shows the average number of crossovers 
cumulated over 5-rain intervals during baseline and for 2 h and 
50 rain after the A M P H  challenge (given when indicated by the 
arrow). AMPH-pretreated rats differed significantly from saline 
pretreated rats, primarily because the former group showed a large 
decrease in locomotion about 30 min after the challenge injection 
(2-way ANOVA with repeated measures, group by time interaction, 
F=2.09,  P<0.001). Right: The right panel depicts the mean 
( ±  SEM) stereotypy ratings (head and limb movements) obtained 
during baseline (interval 0) and then repeatedly after the challenge 
injection of AMPH (see Methods). AMPH-pretreated animals 
showed significantly more intense stereotypy than saline-pretreated 
animals (Mann-Whitney U test on the cumulative ratings, U =  0, 
P<0.002). • Amphe tamine -  pretreated; o control 
after the discontinuation ofpretreatment (compare Fig. 5 
with Figs 2, 3 and 4). 
Withdrawal from A M P H  : Effects on spontaneous 
day~night locomotor activity 
Data from this experiment were first analyzed to deter- 
mine if there was any effect of saline pretreatment, i.e., 
the nonhandled and saline-pretreated controls were com- 
pared. There was no difference between nonhandled and 
saline-pretreated animals on any measure, and therefore 
these groups were pooled to form one control group for 
all subsequent analyses. In addition, to simplify data 
presentation, spontaneous locomotor activity in AMPH- 
pretreated and control rats were averaged over days 2-3, 
days 4-7 or days 24-28 to form just three AMPH "with- 
drawal" groups. 
Figure 6 shows the average spontaneous locomotor 
activity counts ("crossovers") for control and AMPH- 
Fig. 6A-C. Mean spontaneous locomotor activity in AMPH- 
pretreated (closed symbols) and control animals (open symbols) : 
A 2-3 days (N= 32 and 24, respectively), B 4-7 days (N= 16/group) 
and C 23 28 days (N= 16/group) after the discontinuation of pre- 
treatment. The panels on the left represent the average number of 
crossovers cumulated over 30-rain intervals across the day/night 
cycle. The 10 h lights off period, which began at 19:00 hours, is 
illustrated by the solid black bar on the horizontal axis, and daytime 
hours by the open bar. The panels on the right show the average 
( + SEM) number of crossovers cumulated over 7 h before the lights 
went off (11:00-19:00 hours), the initial 3 h after the lights went 
off (19:00-22:00 hours), the middle of  the night (22:00-3:30 
hours), the last 1.5 h prior to the lights going on (3 : 30-5:00 hours) 
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and the 2 h after the lights came back on (5:00-7:00 hours). Data 
for the remaining 3.5 daytime hours were excluded because of the 
disturbance associated with data collection and animal care that 
occured at this time. A 2-3 days. AMPH-pretreated animals were 
significantly less active than controls both during the daytime 
(2-way ANOVA with repeated measures on the initial 10 h lights-on 
period, effect of group, F = 5.38, P <  0.024, effect of time, F =  24.8, 
P<0.001, interaction non-significant), and at night (ANOVA on 
lights-off period, group F = 15.8, P < 0.001, time F = 11.2, P < 0.001 
and interaction F=3.4,  P<0.001). The significant group by time 
interaction for nocturnal activity indicates that AMPH-pretreated 
animals did not differ from controls throughout the entire night, 
and this is best illustrated in the bar graph to the right. In the right 
panel asterisks (*) indicate times at which AMPH-pretreated ani- 
mals differed significantly from controls. For the initial daytime 
period t=  2.32, P=0.024, but during the initial lights-off period 
(19:00-22:00 hours) there were no significant group differences 
(t = 1.82). During the rest of  the night AMPH-pretreated rats were 
significantly less active than controls (22:00-3:30 hours, t=  3.93, 
P < 0.001 ; 3 : 30-5:00, t = 5.85, P < 0.001), and they remained less 
active after the lights came on again (5: 00-7:00, t = 3.01, P = 0.004). 
B 4-7 days. AMPH-pretreated animals were not significantly less 
active than controls during the lights-on period (ANOVA) but were 
significantly hypoactive at night (ANOVA on nocturnal activity, 
group F=17.7,  P<0.001, time F=5.42,  P<0.001, interaction 
F =  2.07, P < 0.004). Again, the panel to the right shows that there 
were no significant group differences during the initial lights-off 
period (19:00-22:00 hours, t = 2.01), but during the rest of the night 
AMPH-pretreated rats were significandy tess active than controls 
(22:00-3:30 hours, t=4.47, P<0.001;  3:30-5:00 hours, t=4.05, 
P<0.001). C 24-28 days. By 24-28 days there was no longer 
any effect of AMPH pretreatment on either daytime or nocturnal 
activity. For nocturnal activity, the group F <  1.0 and the group by 
time interaction F =  1.13, P = 0.32. • • Amphetamine - pretreated; 
o [] control 
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Table 1. The mean (± SEM) postmortem tissue concentrations of monoamines and their metabolites, expressed in ng/mg wet tissue weight, 
in control animals that received a "challenge" injection of saline 
NE DA DOPAC HVA 5-HT 5-HIAA 
Caudate-putamen 0.09 + 0.01 20.87 + 0.59 3.20 4= 0.09 1.39 4- 0.08 - - 
Nucleus accumbens 0.44+0.02 12.49+t:0.40 3.46+t-0.09 1.483:0.16 .-- - 
Medial frontal cortex 1.59+1:0.06 0.23+t:0.02 - - 0.91 +0.07 0.56±0.07 
Hypothalamus 7.8 +0.19 0.93+0.05 0.16+0.02 - 1.27±0.12 1.01+0.13 
In Figs. 7 and 8 the postmortem tissue values for all other groups are expressed as a percent of  these values. A dash indicates the compound 
was not quantified 
Abbreviations: NE, norepinephrine; DA, dopamine; DOPAC, dihydroxyphenylacetic acid; HVA, homovanillic acid; 5-HT, 5-hydroxy- 
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Fig. 7A-D. The effect of prctreatment with escalating doses of 
AMPH on the basal (steady state) postmortem tissue concentra- 
tions of monoamines and their metabolites in selected brain regions 
(N=  at least 8/group). The height of  the bars represents the mean 
( ÷  SEM) concentration of compounds plotted as a percent of the 
control group that received a saline challenge (see methods and 
Table 1). The bars" in each panel, from left to right, indicate control 
(C) or AMPH-pretreated animals 3, 7, or 28 days after the discon- 
tinuation of pretreatment. For  each compound in each structure 
statistically significant group differences were determined by con- 
ducting a one-way analysis of  variance, and if indicated by a signifi- 
cant F value (P<  0.05), pairwise comparisons were made using the 
Fisher's LSD test. A heavy horizontal line above some bars indicates 
significant group differences based on the ANOVA. A vertical line 
extending downwards from the heavy horizontal line indicates those 
groups that differed significantly from control, based on the Fisher's 
LSD test (P<0.05). A dagger (t) indicates those groups that dif- 
pretreated animals across the light-dark cycle. Control  
animals showed the same pattern of  day/night locomotor  
activity at all times following the discontinuation of  
pretreatment  (Fig. 6). This was characterized by relative- 
ly little locomotion during the day, a slow increase in 
locomotion as night approached,  a large peak in activity 
immediately following lights-off, a decrease in activity 
during the middle of  the night (but not to daytime levels), 
and finally, a second peak in locomotion 1-2 h prior  to 
DOPAC S-HT 5-HIAA 
fered significantly from AMPH-pretreated animals withdrawn for 
28 days, again based on the Fisher's test (P<0.05). A Caudate- 
putamen: the only significant effect was in the ratio of HVA/DA 
(F= 2.94, P < 0.05), and only AMPH-pretreated rats withdrawn for 
3 or 28 days differed significantly from control (P < 0.05). For HVA, 
F =  2.1, P = 0.12, and for all other compounds F <  1.0. B Nucleus 
accumbens: there was no significant effect of AMPH pretreatment 
for any compound. C Medial frontal cortex: there was no signifi- 
cant effect of AMPH pretreatment for any compound. All F's < 1.0. 
D Hypothalamus: the only significant ANOVA was for NE 
(/7= 33.2, P<0.001). AMPH-pretreated rats withdrawn for 3 or 7 
days had significantly lower hypothalamic NE concentrations than 
either controls or rats withdrawn for 28 days (P<0.05). Hypo- 
thalamic NE in the 3-day group was also significantly lower than 
in the 7-day group (P<  0.05). The group withdrawn for 28 days did 
not differ from controls. For all other compounds F <  1.0. 
lights-on. When the lights came on again locomotor  
activity fell to very low levels. 
AMPH-pre t rea ted  animals were significantly less ac- 
tive than controls (Fig. 6). Between 2 and 3 days after the 
discontinuation of  A M P H  pretreatment  A M P H -  
pretreated rats were less active than controls during both 
the day and night periods (Fig. 6A), but  by 4-7 days only 
nocturnal locomotor  activity was depressed (Fig. 6B). 
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Fig. 8A-D. The effect of pretreatment with escalating doses of 
AMPH on the postmortem tissue concentrations of monoamines 
and their metabolites in selected brain regions 40 min following a 
challenge injection of 2.6 mg/kg AMPH. The height of the bars 
represents the mean (+SEM) concentration of the compounds 
plotted as a percent of control animals that did not receive an 
AMPH challenge (see Table 1). The bars in each panel, from left 
to right, indicate: (1) control animals that did not receive an AMPH 
challenge (group C; N = 16); (2) control animals that received an 
AMPH challenge (group O; N = 15); and AMPH-pretreated ani- 
mals that received a challenge injection of AMPH, (3) 3 days (group 
3; N= 8); (4) 7 days (group 7; N= 8); or (5) 28 days (group 28; 
N= 8) after the discontinuation of pretreatment. A heavy horizontal 
line above some bars indicates there were significant group differen- 
ces for that compound, based on a one-way ANOVA. A vertical line 
extending downwards from the heavy horizontal line indicates 
groups that differed significantly from control animals that received 
saline (Fisher's test, P < 0.05). The daggers (?) indicate groups that 
differed significantly from the control animals that received AMPH 
(group 0). A Caudate-putamen: for NE, F <  1.0 (non-significant). 
For DA, F=9.06, P<0.001. The challenge injection of AMPH 
significantly increased DA concentrations in control animals, and 
AMPH-pretreated animals withdrawn for 28 days; but not in 
AMPH-pretreated rats withdrawn for 3 or 7 days. DA concentra- 
tions in AMPH-pretreated rats withdrawn for 3 or 7 days were sig- 
nificantly less than in control animals challenged with AMPH. 
in l o c o m o t o r  ac t iv i ty  when  the l ights  first went  out ,  bu t  
this was no t  sus ta ined ,  a n d  du r ing  the midd l e  a n d  end o f  
the l ights-off  pe r iod  l o c o m o t o r  ac t iv i ty  was m a r k e d l y  
depressed  in A M P H - p r e t r e a t e d  ra ts  (Fig.  6A, B). By 
4 weeks  la te r  g r o u p  differences in n o c t u r n a l  l o c o m o t o r  
ac t iv i ty  were no  longer  a p p a r e n t  (Fig.  6C). 
The  behav io r a l  effects o f  the  2.6 m g / k g  A M P H  chal-  
lenge were  s imi lar  to expe r imen t  1. As  expected ,  the  
A M P H  chal lenge  p r o d u c e d  s ignif icant ly  grea te r  s tereo-  
typed  behav io r  28 days  af te r  the  d i s c o n t i n u a t i o n  o f  pre-  
t r e a t m e n t  than  af ter  3 d a y s ;  a l t h o u g h  in c o n t r a s t  to 
expe r imen t  1 an ima l s  w i t h d r a w n  for  3 days  h a d  signifi- 
DA 5-HT 
The 3-day group also differed significantly from the 28-day group 
(P < 0.05). For DOPAC, F =  31.5, P < 0.001. The AMPH challenge 
significantly decreased DOPAC in all groups (P<0.05), but in 
AMPH-pretreated rats withdrawn for 3 days the effect of the 
AMPH challenge was significantly less than in control animals. 
B Nucleus accumbens: for NE, F=2.54, P<0.05. The AMPH 
challenge significantly increased NE concentrations in control rats, 
and in AMPH-pretreated rats withdrawn for 7 or 28 days. There 
was no significant effect of AMPH pretreatment. For DA, F =  9.33, 
P<  0.001. The AMPH challenge significantly elevated DA in all 
groups, but to a significantly lesser extent in the 3-day group than 
in controls. For DOPAC, F =  31.1, P < 0.001. The AMPH challenge 
significantly decreased DOPAC in all groups, and there was no 
effect of AMPH pretreatment. C Medial frontal cortex : there was 
no significant effect of AMPH pretreatment or the AMPH challenge 
on any compound. D Hypothalamus: for NE, F =  19.1, P<0.001. 
The AMPH challenge did not have a significant effect on NE 
concentrations in control animals, or the 28-day group. However; 
NE was significantly decreased in the 3- and 7-day groups, relative 
to the saline challenge control group, the AMPH challenge control 
group, and the 28-day withdrawn group (P<0.05). In addition, 
the 3- and 7-day groups differed significantly from one another 
(Fisher's LSD tests, P<0.05). There was no significant effect 
of the AMPH challenge or AMPH pretreatment on DA or 5-HT 
concentrations in the hypothalamus (F's < 1.0) 
can t ly  h igher  s t e r eo typy  ra t ings  than  cont ro ls .  As  in 
expe r imen t  1, however ,  on ly  the  28-day g r o u p  showed  a 
s ignif icant  decrease  in " s t e r e o t y p y  phase"  l o c o m o t o r  ac-  
t ivi ty (da t a  no t  shown).  
Withdrawal  f r o m  A M P H . "  Ef fects  on the pos tm or t em  
tissue concentrations o f  monoamines  and monoamine  
metabol i tes  
Table  1 shows the average  concen t r a t i ons  (ng/mg)  o f  
m o n o a m i n e s  and  thei r  me tabo l i t e s  in c on t ro l  an ima l s  
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"challenged" with saline (3, 7 and 28 day groups pooled). 
Figure 7 shows the average postmortem tissue concentra- 
tions of monoamines and their metabolites in AMPH- 
pretreated animals "challenged" with saline 3, 7 or 28 
days after the cessation of pretreatment. These latter 
values are expressed as a per cent of the average levels in 
saline "challenged" control animals; i.e., as a percent of 
the values in Table 1. The only statistically significant 
changes in the basal postmortem tissue levels of these 
compounds were: (1) an increase in the ratio of HVA/ 
DA in the caudate-putamen of AMPH-pretreated rats 
withdrawn for 3 or 28 days (Fig. 7A); and (2) a decrease 
in hypothalamic NE concentrations 3 and 7 days after 
the discontinuation of pretreatment. By 28 days hypo- 
thalamic NE concentrations had returned to normal 
(Fig. 7D). Based on predictions from previous studies 
involving stress-induced behavioral depression (Weiss et 
al. 1980), we also tested for a correlation between NE 
concentrations and locomotor activity. As predicted, 
there was a significant positive correlation between hypo- 
thalamic NE concentrations and late night locomotor 
activity (r= +0.47, F =  10.6, P<0.003). In contrast, nu- 
cleus accumbens NE concentrations were negatively cor- 
related with late night locomotor activity (r----0.30, 
F =  3.9, P = 0.056). 
Figure 8 shows the effect of an AMPH challenge on 
the average postmortem tissue concentrations of mono- 
amines in AMPH-naive control animals, and AMPH- 
pretreated rats withdrawn for 3, 7 or 28 days. The data 
are again expressed as a percent of control animals 
"challenged" with saline. Thus, comparison of control 
animals "challenged" with saline (group C in Fig. 8) and 
control animals challenged with AMPH (group 0 in 
Fig. 8 - for zero withdrawal) illustrates the effect of an 
AMPH challenge in AMPH-naive animals. This can be 
compared with the effects of an AMPH challenge in 
AMPH-pretreated rats that received their last pretreat- 
ment injection 3, 7 or 28 days earlier (groups 3, 7 and 28 
in Fig. 8). In the caudate-putamen (Fig. 8A) there was 
no effect of AMPH pretreatment or the AMPH challenge 
on NE concentrations. The AMPH challenge did 
produce a significant increase in caudate-putamen DA 
concentrations in AMPH-naive control animals (group 
0), and this was significantly attenuated in AMPH- 
pretreated animals 3 and 7 days after the discontinuation 
of drug treatment, but not 28 days later. In fact, the 3 and 
7 day groups did not differ significantly from the saline 
"challenge" control group (group C in Fig. 8A). The 
AMPH challenge also produced a large decrease in 
caudate-putamen DOPAC concentrations in all groups, 
and this effect was significantly attenuated in AMPH- 
pretreated rats withdrawn for only 3 days (Fig. 8A). 
The AMPH challenge elevated NE concentrations in 
the nucleus accumbens in all groups, except the 7-day 
group, but there was no statistically significant effect of 
AMPH pretreatment (Fig. 8B). As in the caudate- 
putamen, however, DA concentrations in the nucleus 
accumbens were elevated to a lesser extent in AMPH- 
pretreated rats withdrawn for 3 days than in the control 
animals challenged with AMPH, and this effect was no 
longer evident at 28 days. The AMPH challenge de- 
creased nucleus accumbens DOPAC concentrations to 
the same extent in all groups. 
In the frontal cortex there was no significant effect of 
AMPH pretreatment or the AMPH challenge on the 
concentrations of NE, DA or 5-HT (Fig. 8C). In the 
hypothalamus (Fig. 8D) the AMPH challenge did not 
affect NE concentrations in AMPH-naive control rats, 
but in AMPH-pretreated rats NE concentrations were 
significantly decreased 3 and 7, but not 28 days, after 
the discontinuation of pretreatment. There was no sig- 
nificant effect of AMPH pretreatment or the AMPH 
challenge on DA or 5-HT concentrations in the hypo- 
thalamus. 
Discussion 
The discontinuation of chronic escalating dose AMPH 
treatment resulted in both transient and persistent 
changes in brain and behavior. Spontaneous nocturnal 
locomotor activity was transiently depressed during 
AMPH withdrawal, especially towards the end of the 
lights-off period. This behavioral depression was most 
pronounced during the first 2 days of withdrawal, was 
still evident up to 1 week later, but had dissipated within 
4 weeks. Catecholamine concentrations in some struc- 
tures were altered in association with nocturnal hypo- 
activity. For example, the basal postmortem tissue con- 
centration of NE was significantly reduced in the hypo- 
thalamus 3 and 7 days after the cessation of AMPH 
pretreatment, but returned to control levels by 4 weeks. 
Transient changes in caudate-putamen and nucleus ac- 
cumbens DA concentrations were only evident after a 
challenge injection of AMPH. In control animals an 
AMPH challenge increased the postmortem tissue con- 
centration of DA in the caudate-putamen and nucleus 
accumbens, but this effect was significantly attenuated in 
AMPH-pretreated animals between 3 and 7 days of with- 
drawal. Four weeks later an AMPH challenge increased 
DA concentrations to the same extent in AMPH- 
pretreated and control animals. In contrast, there was no 
effect of AMPH withdrawal on 5-HT concentrations in 
any of the structures studied. 
Persistent behavioral changes produced by past ex- 
perience with AMPH were not seen in spontaneous loco- 
motor activity, but became apparent when animals re- 
ceived a subsequent challenge injection of AMPH. Pre- 
treatment with escalating doses of AMPH produced a 
marked behavioral hypersensitivity to a challenge injec- 
tion of AMPH. With the challenge dose of AMPH used 
here behavioral sensitization was characterized by more 
intense AMPH-induced stereotyped behavior (stereo- 
typed sniffing and stereotyped head and limb move- 
ments) in AMPH-pretreated animals than in saline- 
pretreated controls. Interestingly, for the first week of 
withdrawal, during which time spontaneous locomotor 
activity was depressed, there was no difference between 
AMPH pretreated and control animals in their loco- 
motor response to an AMPH challenge, and focused 
stereotypy was not evident in either group. By 2 weeks, 
however, behavioral sensitization was fully developed 
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and AMPH-pretreated animals showed a much larger 
response to the AMPH challenge than controls - and this 
hypersensitivity to AMPH persisted undiminished for at 
least 1 year. The only persistent change in brain mono- 
amine or monoamine metabolite concentrations detected 
here was in the ratio of HVA to DA in caudate-putamen, 
which was significantly elevated in AMPH-pretreated 
rats 3 and 28 days after the discontinuation of AMPH 
pretreatment (Robinson and Camp 1987; also see Camp 
and Robinson 1988). 
Withdrawal from A M P H -  transient behavioral 
depression 
There have been relatively few studies on the behavioral 
and neurochemical consequences of AMPH withdrawal. 
Behavioral depression has been reported after the discont- 
inuation of continuous access to AMPH in drinking 
water (Herman et al. 1971; Tonge 1974; Lynch et al. 
1977; Lynch and Leonard 1978), but in these studies it 
is difficult to ascertain exactly what dose the animal 
received, whether it was neurotoxic, or under what con- 
ditions behavioral depression was manifest. Nocturnal 
hypoactivity has also been reported following intermit- 
tent injections of a constant low dose of AMPH (Segal 
and Mandell 1974), but this effect was not as pronounced 
or persistent as reported here. Nevertheless, one consis- 
tent characteristic of the AMPH withdrawal syndrome 
appears to be a transient behavioral depression that lasts 
for varying lengths of time, depending on the nature of 
the pretreatment regimen (Utena 1966). Other features of 
the AMPH withdrawal syndrome that may be related to 
behavioral depression include changes in motivational 
and affective state. For example, the discontinuation of 
chronic treatment with AMPH or cocaine results in defi- 
cits in self-stimulation reward (Leith and Barrett 1976; 
Simpson and Annau 1977; Kokkinidis and Zacharko 
1980; Cassens et al. t981; Kokkinidis et al. 1986), op- 
erant behavior reinforced by a sweetened drinking solu- 
tion (Carroll and Lac 1987) and reactivity to novel stim- 
uli (Schreiber et al. 1976). 
The behavioral deisression described here was not a 
simple disturbance in motor function, because the ani- 
mals were fully capable of generating high levels of loco- 
motor activity (also see Kokkinidis et al. 1986). AMPH- 
pretreated animals showed a normal large increase in 
locomotor activity when the lights first went out, but as 
the night progressed they did not sustain as high a level 
of activity as controls, and did not show a normal in- 
crease in locomotion during the last hour and a half of 
the lights-off period. It has been suggested that the initial 
increase in locomotor activity seen just after the lights go 
off, and the early morning increase in activity seen just 
before the lights go on, are mediated by two independent 
circadian oscillators (Pittendrigh and Daan 1976). It is 
interesting to speculate, therefore, that one oscillator 
may be more susceptible to disruption by AMPH pre- 
treatment than the other, thus accounting for the dif- 
ferential effect of AMPH pretreatment on early versus 
late night locomotor activity. Indeed, studies in which 
animals were given continuous access to AMPH in their 
drinking water suggest that AMPH can have different 
effects on these two oscillators (Honma et al. 1986), but 
it is difficult to compare studies using such different 
treatment regimens. 
The inability of AMPH-pretreated animals to sustain 
high levels of locomotor activity throughout the night is 
reminiscent of the behavioral depression produced by 
exposure to uncontrollable stress. There are a number of 
different chronic stress paradigms that have been used to 
model clinical depression, and all of these produce be- 
havioral depression in a variety of tasks (Weiss and 
Simson 1986; Zacharko and Anisman 1989). Similar to 
the behavioral depression reported here, stress-induced 
behavioral depression is not characterized by an inability 
to initiate behavior, but to sustain it. In reviewing studies 
on stress-induced depression Anisman (1984) has noted 
that "when confronted with a strong stimulus animals 
are able to initiate an active response, regardless of their 
stress history. However, animals that previously had 
been exposed to uncontrollable stress encountered great 
difficulty in sustaining active responses" (p 411). The 
behavioral depression produced by uncontrollable stress 
is short-lived (24-72 h) relative to that reported here, but 
the apparent similarity between the two phenomena, and 
the interchangeability of AMPH and stress in producing 
sensitization (Antelman et al. 1980), suggest they could 
be the result of related neurochemical adaptations (see 
below). 
One of the most consistent neurochemical conse- 
quences of uncontrollable stress, and one that is strongly 
correlated with stress-induced behavioral depression, is 
a transient depletion of brain NE. For example, the 
magnitude of stress-induced behavioral depression is 
positively correlated with a decline in the postmortem 
tissue concentrations of NE in the hypothalamus (Weiss 
et al. 1980), which receives most of its NE input from the 
lateral tegmental NE system. The strongest correlation, 
however, is with locus coeruleus NE concentrations 
(Weiss and Simson 1986). Unfortunately, locus coeruleus 
NE was not measured here, but as in studies on stress- 
induced behavioral depression, hypothalamic NE was 
depleted during AMPH withdrawal, and there was a 
significant positive correlation between nocturnal loco- 
motor activity and hypothalamic NE concentrations. A 
decrease in whole brain and regional NE concentrations 
following the discontinuation of chronic AMPH treat- 
ment has been reported before (Herman et al. 1971; 
Tonge 1974; Short and Shuster 1976; Lynch et al. 1977; 
Segal et al. 1980). This is the first report, however, to 
show a clear relationship between the time course of 
post-AMPH withdrawal behavioral depression and the 
time course of a depletion in hypothalamic NE con- 
centrations in animals given doses of AMPH known to 
be non-neurotoxic. 
Reports that antidepressant drugs alleviate symp- 
toms of both stress-induced behavioral depression and 
post-AMPH withdrawal behavioral depression are con- 
sistent with the idea that these are related phenomena 
(Seltzer and Tonge 1975; Lynch and Leonard 1978; 
Kokkinidis and Zacharko 1980; Zacharko et al. 1984; 
489 
Zacharko and Anisman 1989). On the other hand, the 
neural adaptations to chronic stress and chronic AMPH 
treatment may be very different. For example, it has been 
hypothesized that following uncontrollable stress the de- 
pletion of NE is indicative of increased NE neurotrans- 
mission in NE terminal regions (Weiss and Simson 1986), 
and similar changes in NE neurotransmission are asso- 
ciated with withdrawal from opiates and benzodiaze- 
pines (Aghajanian 1978; Redmond and Huang 1982; 
Roth et al. 1982; Grant et al. 1985). In contrast, the 
limited evidence available suggests NE "turnover" in 
terminal regions is decreased during post-AMPH with- 
drawal depression. Not only are the postmortem tissue 
concentrations of NE reduced in NE terminal regions, 
but so is the concentration of the NE metabolite, MHPG 
(Cassens et al. 1979). Furthermore, urinary MHPG is 
decreased during AMPH withdrawal in humans (Schitd- 
kraut et al. 1971 ; Watson et al. 1972). One exception to 
the idea that NE "turnover" is decreased during AMPH 
withdrawal is a report of elevated MHPG in the cerebel- 
lum up to 10 days after the discontinuation of intermit- 
tant low dose AMPH treatment in rats (Sorensen et al. 
1985). 
This brief discussion emphasizes that the literature on 
changes in NE neurotransmission during withdrawal 
from AMPH (or stress, or opiates) is incomplete, 
sometimes contradictory, and therefore confusing. It 
should be kept in mind, however, that in most studies of 
these phenomena only neurotransmitter and/or neuro- 
transmitter metabolite content has been measured in 
postmortem tissue, and at only one point in time. The 
postmortem tissue concentrations of monoamines were 
measured here as a first step in relating changes in brain 
neurochemistry to the dynamic changes in behavior seen 
over time during AMPH withdrawal, and in anticipation 
of subsequent in vivo neurochemical experiments utiliz- 
ing microdialysis. Information about the postmortem 
tissue concentrations of neurotransmitters is required to 
interpret changes in the extracellular concentrations of 
neurotransmitters and neurotransmitter metabolites. 
However, by themselves, postmortem tissue measures are 
not only insensitive indicators of neurotransmission, but 
they can sometimes be misleading (Commissiong 1985). 
Thus, more direct in vivo measures of neurotransmitter 
dynamics will be required to determine if and how NE 
neurotransmission is altered during AMPH withdrawal. 
It is also important to note that other neurotrans- 
mitter systems are probably altered during AMPH with- 
drawal. For example, the present study provides, to our 
knowledge, the first neurochemical evidence of a rela- 
tionship between the time course of post-AMPH with- 
drawal depression and alterations in mesotelencephalic 
DA systems. The ability of an AMPH challenge to alter 
DA concentrations in the caudate-putamen and nucleus 
accumbens was attenuated in AMPH-pretreated animals 
3-7 days after the discontinuation of pretreatment, but 
not 28 days later. Although more reliable measures of 
DA dynamics will be required to determine the exact 
nature of the alteration in DA neurotransmission, the 
evidence provided here suggests that mesotelencephalic 
DA systems are relatively unresponsive during AMPH 
withdrawal. Given the proposed role of nucleus accum- 
bens DA in motivated behavior (Wise and Rompre 1989; 
cf. Berridge et al. 1989), it seems reasonable to suggest 
that decreased responsivity in DA systems may contrib- 
ute to the marked anhedonia reported in humans during 
AMPH withdrawal (Gawin and Ellinwood 1988), and 
the attenuation in electrical brain self-stimulation seen in 
animals (Leith and Barrett 1976; Cassens et al. 1981; 
K0kkinidis et al. 1986). 
Withdrawal from A M P H -  persistent behavioral 
sensitization 
Persistent changes in behavior as a result of past ex- 
perience with AMPH were not apparent in spontaneous 
locomotor activity patterns, but as expected, when ani- 
mals received a challenge injection of AMPH it was 
obvious they had been sensitized (Robinson and Becker 
1986). Of particular interest in the present study is the 
finding that behavioral sensitization, indicated by the 
emergence of focused stereotyped behavior, persisted 
undiminished for at least a year after the discontinuation 
of AMPH pretreatment. This is the strongest evidence to 
date to suggest that non-neurotoxic doses of AMPH may 
change the neural systems that mediate the psychomotor 
stimulant effects of this drug for the life of the animal 
(Robinson and Becker t986). 
It is unlikely that behavioral sensitization is due to 
changes in AMPH disposition (McCown and Barrett 
1980; Robinson and Becker 1986), and the apparently 
permanent sensitization-related changes in behavior 
were not due to AMPH neurotoxicity because neither 
DA or 5-HT were depleted (Seiden and Ricaurte 1987). 
There is, however, considerable evidence in support of 
the hypothesis that presynaptic changes in DA systems 
contribute to AMPH sensitization (Robinson and Becker 
1986 for review). For example, both in vitro superfusion/ 
incubation studies (Robinson and Becker 1982; Robin- 
son et al. 1982; Kolta et al. 1985; Wilcox et al. 1986; 
Castafieda et al. 1988; Yamada et al. 1988; Kolta et al. 
1989; Robinson 1990) and in vivo microdialysis studies 
(Robinson et al. 1988; Kazahaya et al. 1989) have shown 
that stimulated DA release is enhanced in the striatum 
and nucleus accumbens of AMPH-sensitized animals for 
up to 3 months after the cessation of repeated AMPH 
treatment. Whether DA release is still enhanced 
6 months to a year after the discontinuation of pretreat- 
ment is unknown. Nevertheless, no other neural correlate 
of behavioral sensitization has been shown to account for 
as many features of the behavioral phenomenon (Robin- 
son 1988). The obvious challenge for researchers who 
propose that other neural adaptations may underlie be- 
havioral sensitization to AMPH is to establish, for exam- 
ple, whether they persist for as long as the behavioral 
phenomenon - which this study suggests may be for the 
life of the animal. 
Another interesting finding was the length of time 
following the discontinuation of AMPH pretreatment 
that an AMPH challenge failed to produce a sensitized 
behavioral response. A fully sensitized response to the 
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challenge injection of  A M P H  was not  evident until 
2 weeks after the discontinuation of  pretreatment. This 
is consistent with reports that the effects of  prior A M P H  
treatment tend to "grow" in time during withdrawal 
(Hitzemann et al. 1977; Kolta  et al. 1985; Antelman 1988 
for review), and that injections widely spaced in time 
produce more robust sensitization than injections given 
close together in time (Post 1980). One explanation for 
the gradual emergence o f  sensitization is that the neural 
changes underlying sensitization continue to develop for 
some time following the cessation of  pretreatment. This 
idea is supported by Kolta et al. (1985), who showed that 
AMPH-st imulated DA release from striatal tissue was 
not  significantly enhanced 3 days after the discontinua- 
tion of  A M P H  pretreatment, but was enhanced 15-30 
days later. An alternative explanation, however, is that 
the transient neurochemical changes underlying post- 
A M P H  withdrawal depression can "mask" or suppress 
those responsible for sensitization, perhaps by a dias- 
chisis-like process. Evidence of  sensitization may become 
apparent,  therefore, only as these more transient effects 
dissipate. Whichever the case, studies on the neural cor- 
relates of  sensitization that focus on transitional periods 
of  time, early during withdrawal, may reflect behavioral 
depression rather than sensitization; or some complex 
interaction of  the two. In studying the neural basis of  
behavioral sensitization it would seem most prudent  to 
use animals that have been withdrawn long enough for 
behavioral depression to dissipate. Otherwise it will be 
very difficult to dissociate neural changes associated with 
transient pos t -AMPH withdrawal depression from those 
associated with persistent behavioral sensitization. 
In summary, following the discontinuation of  treat- 
ment with escalating doses of  A M P H  rats showed a 
decrease in spontaneous nocturnal locomotor  activity 
that lasted at least a week following the last injection of  
AMPH,  but  dissipated 2-4 weeks later. Pos t -AMPH 
withdrawal behavioral depression in rats may represent, 
therefore, an animal analogue of  the "distress syndrome" 
seen in addicts during withdrawal from chronic psycho- 
motor  stimulant drug use (Gawin and Ellinwood 1988; 
Kokkinidis 1988). A M P H  withdrawal in humans is also 
characterized by symptoms of  depression and alterations 
in catecholamine function. The transient changes in 
brain and behavior described here were robust, lasted at 
least 1 week, and were easily quantified. This paradigm 
may prove valuable, therefore, in relating neural adapta- 
tions provoked by A M P H  withdrawal to behavioral de- 
pression. In addition to these transient effects, A M P H  
also had very persistent, if not  permanent,  effects on the 
responsiveness to a subsequent A M P H  challenge, Thus, 
this paradigm allows one to study not only the initial 
"distress syndrome" but also the persistent consequences 
of  past A M P H  use. In developing potential therapeutic 
interventions for A M P H  withdrawal it may be especially 
important  to consider the interaction between post- 
A M P H  withdrawal depression and A M P H  sensitization. 
For  example, the antidepressant drug desipramine has 
been reported to facilitate cocaine abstinence when given 
early during withdrawal (Gawin et al. t989), but  to pre- 
cipitate relapse when given after 1-6 months of  absti- 
nence (Weiss 1988). This latter effect may be related to 
the sensitizing properties of  desipramine itself (FiNger 
and Phillips 1981 ; Maj et al. 1987), and raises the possi- 
bility that some treatments which are effective in alleviat- 
ing transient depressive symptoms may later exacerbate 
A M P H  craving and/or  A M P H  sensitization. It will be 
important  to delineate potential interactions of  this kind 
in evaluating new therapeutic approaches to A M P H  
abuse. 
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